The number of innovative drugs and medical devices approved in the first half of the year has significantly increased year-on-year

According to the National Medical Products Administration, in the first half of this year, China approved 43 innovative drugs and 45 innovative medical devices, representing year-on-year increases of 59% and 87%, respectively. The benefits of reform policies are being transformed into driving forces for industrial development. Since last year, the National Medical Products Administration has launched pilot projects to optimize the supplementary application reform in 11 provincial-level bureaus, reducing the review time for supplementary applications that require inspection from 200 working days to 60 working days, while also exploring the completion of clinical trial review and approval for key innovative drugs within 30 working days. In the first half of the year, 70 new pediatric drugs and 21 drugs for rare diseases were approved